Bintrafusp alfa with cCRT followed by bintrafusp alfa versus placebo with cCRT followed by durvalumab in patients with unresectable stage III NSCLC: A phase 2 randomized study

By sjmartinez • October 6, 2023

Vokes EE, Mornex F, Sezer A, Cheng Y, Fang J, Baz DV, Cil T, Adjei AA, Ahn MJ, Barlesi F, Felip E, Garon EB, Audhuy F, Ito R, Sato M, Eggleton SP, Martin CM, Reck M, Robinson CG, Paz-Ares L. Bintrafusp alfa with cCRT followed by bintrafusp alfa versus placebo with cCRT followed by durvalumab in patients with unresectable stage III NSCLC: A phase 2 randomized study. J Thorac Oncol. 2023 Oct 3:S1556-0864(23)02262-1. doi: 10.1016/j.jtho.2023.09.1452. Epub ahead of print. PMID: 37797733.

Tags: bifunctional, bintrafusp alfa, concurrent chemoradiotherapy, Hematology/Oncology, non-small-cell lung cancer, Publications, TGF-β

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer

Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, Punekar SR, Barve M, Pelster M, Herzberg B, Azad NS, Hecht JR, Ou[...]

Social wellbeing, loneliness, and symptom burden in head and neck cancer survivors: a latent class analysis

Brauer ER, Choi KR, Petersen L, Ganz PA, St John MA, Wong DJ, Martin EJ. Social wellbeing, loneliness, and symptom burden in head and neck[...]

Achieving timely treatment for early-stage non-small cell lung cancer: Factors associated with delayed surgical resection and proposed quality benchmarks

Tupper HI, Bhattacharjee J, Sarovar V, Amara D, Schmittdiel JA, Quesenberry CP, Cummings AL, Velotta JB, Sakoda LC. Achieving timely treatment for early-stage non-small cell[...]